CAR T-Cell Therapy Market worth $13.56 billion by 2031
The report "CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031" The CAR T-Cell Therapy market is projected to reach USD 13.56 billion by 2031 from USD 6.78 billion in 2026, at a CAGR of 14.9% during the forecast period
Browse 300 market data Tables and 30 Figures spread through 280 Pages and in-depth TOC on "CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/car-t-cell-therapy-market-47772841.html
The CAR T-cell therapy market is predicted to grow at a CAGR of 14.9% during the forecast period of 2026 to 2031. The important factors impacting market growth are the rising prevalence of cancer and increasing funding and investments for therapy development. Additionally, the rising technological advancements in CAR T-cell therapies is likely to uplift market growth in coming years.
Products segment held the highest share of the CAR T-cell therapy market
Based on the products, the CAR T-cell therapy market is segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. Carvykti accounted for the largest market share in 2025. Carvykti’s increasing adoption for relapsed or refractory multiple myeloma is supported by strong clinical efficacy, deep response rates, and durable remission outcomes demonstrated in clinical studies. In addition, recent label expansions into earlier lines of therapy and increasing treatment capacity across certified treatment centers have further accelerated its adoption.
High growth of indications segment attributed to B-Cell Lymphoma (BCL).
Based on indications, the CAR T-cell therapy market is broadly segmented into Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, B-Cell Lymphoma (BCL), and other indications. In 2025, B-Cell Lymphoma (BCL) accounted for the largest share of the CAR T-cell therapy market. The high growth of this segment is attributed to the increasing prevalence of B-cell Lymphomas providing a major patient pool for the growth of CAR T-cell therapies.
CD19 segment dominates the target segment of the CAR T-cell therapy market
Based on the target, the CAR T-cell therapy market is segmented into BCMA, CD19, CD19/20, CD7, and other targets. In 2025, the CD19 segment accounted for the highest share of the CAR T-cell therapy market. CD19 is a protein expressed on the surface of B-cells, including malignant B-cell lymphomas. These cancers are relatively common, making CD19 a prominent target for CAR T-cell therapies, thereby driving the growth of the market.
North America exhibited the most substantial market growth during the forecast period.
North America accounted for the largest share of the CAR T-cell therapy market in 2025. The region leads the CAR T-cell therapy market due to advanced healthcare infrastructure, early adoption due to early US FDA regulatory approvals of all CAR T-cell therapy drugs and significant investments in CAR T-cell therapy research and development.
The global CAR T-cell therapy market features key market players actively competing for market share, such as Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), and JW (Cayman) Therapeutics Co. Ltd (China).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the CAR T-Cell Therapy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
